Investment Rating - The report maintains an "Accumulate" rating for the company [7]. Core Views - The company is expected to achieve revenue of 6.7 billion RMB and a net profit attributable to the parent company of 1.739 billion RMB in 2025, reflecting year-on-year growth of 9%, 12%, and 14% respectively [1]. - The company plans to distribute approximately 1.74 billion RMB in dividends, which accounts for 100% of the net profit attributable to the parent company [1]. - The report highlights the company's focus on "four restructurings" to drive continuous sales and profit growth, with an emphasis on expanding the Ejiao category and developing new health consumer products [1][3]. Revenue Growth - The Ejiao series is projected to grow by 12% in revenue for 2025, with a gross margin increase of 1.2 percentage points to 74.8% [2]. - Specific product growth estimates include a 5-10% increase for Ejiao blocks, approximately 15% for Ejiao syrup, flat growth for Ejiao cakes, and over 40% for Ejiao powder [2]. - The company anticipates maintaining double-digit revenue growth for the Ejiao series from 2026 to 2027, driven by consumption recovery and product expansion [2]. Strategic Developments - The company is accelerating its expansion in the tonic product category, forming strategic partnerships for various products including deer antler and meat corydalis [3]. - A significant investment of approximately 1.5 billion RMB is planned for the construction of a health consumer products industrial park, indicating a strategic shift towards health consumer products [3]. Financial Performance - The report notes a decrease in accounts receivable and an increase in operating cash flow, with a net operating cash flow of 2.29 billion RMB in 2025, exceeding net profit due to a decline in accounts receivable [4]. - The sales, management, and R&D expense ratios for 2025 are projected at 32.0%, 7.2%, and 4.1% respectively, indicating ongoing optimization of sales expenses [4]. Earnings Forecast - The company’s net profit attributable to the parent company is forecasted to be 1.999 billion RMB in 2026, with a growth rate of 14.97% [11]. - The report adjusts the revenue forecast upwards due to higher-than-expected Ejiao sales, while slightly lowering profit forecasts for 2026 and 2027 [5]. - The target price for the company is set at 77.57 RMB, based on a PE ratio of 25x for 2026 [5].

Core Viewpoint - Dong'e Ejiao plans to invest 1.485 billion yuan in a health consumer goods industrial park, marking one of its largest single investments in recent years [1][3] Group 1: Investment Details - The investment includes 1.421 billion yuan for fixed assets and 64 million yuan for liquidity support [1] - The project will cover an area of 406,800 square meters with a construction area of approximately 151,100 square meters, and is expected to take 22 months to complete [3] - This investment aligns with the company's "1238" strategy, which aims to develop a dual-driven growth model of pharmaceuticals and health consumer goods [3] Group 2: Business Strategy - The health consumer goods sector is characterized by diverse demand and rapid product iteration, necessitating higher standards for R&D, quality, and agile supply chains [3] - The existing industrial park faces limitations in expansion and capacity bottlenecks, prompting the need for new facilities to meet the fast-paced development of health consumer goods [3] - The new investment is seen as a strategic move to capitalize on the growing health industry and the trend of "younger health consumption" [3] Group 3: Financial Implications - The investment will consume a significant portion of the company's cash reserves, which stood at approximately 8.2 billion yuan as of the end of Q3 last year [6] - The shift towards heavier asset allocation may lead to a decline in fixed asset turnover during the construction phase, potentially impacting short-term profitability [6] - As of February 11, the company's stock price was 55.44 yuan, with a market capitalization of 35.7 billion yuan, reflecting an 18% decline over the previous year [6] Group 4: Market Competition - Investors express mixed opinions on the investment, with concerns about the impact on the company's balance sheet and liquidity [4] - Competitors in the health consumer goods space include Kunming Pharmaceutical, Yunnan Baiyao, and others, which may pose challenges for Dong'e Ejiao in achieving expected performance [7]

Core Viewpoint - Dong-E E-Jiao has confirmed its absence from the current bull market, with a year-to-date decline of 18% as of December 22, 2025. The company needs to identify new growth points, such as E-Jiao paste, male products, and international expansion, to regain momentum [1][12][13]. Stock Performance - As of December 22, 2025, Dong-E E-Jiao's stock closed at 49.25 yuan, reflecting a total market capitalization of 31.72 billion yuan. The stock has seen an 18% decline since the beginning of the year, contrasting sharply with the overall A-share market, where over 4,300 stocks recorded positive gains [2][14]. - The company has initiated a share buyback plan, intending to use 100 million to 200 million yuan to repurchase shares at a maximum price of 72.08 yuan per share. This is expected to involve the repurchase of approximately 138,730 to 277,470 shares, representing 0.22% to 0.43% of the total share capital [2][15]. Dividend Policy - Dong-E E-Jiao plans to distribute a cash dividend of 12.69 yuan per 10 shares, totaling approximately 817 million yuan, which indicates a high payout ratio. From 2020 to 2024, the company has consistently maintained a high dividend payout ratio, with a total cash dividend of 1.96 billion yuan in 2020, increasing to 15.55 billion yuan in 2024 [3][15][16]. Historical Context - Dong-E E-Jiao was once regarded as the "Moutai of medicine," experiencing a long-term bull market. However, after a series of price increases that led to a disconnect between product pricing and consumer demand, the company faced significant challenges, including a net profit loss of 455 million yuan in 2019 [4][18]. - The leadership transition from Qin Yufeng to Gao Dengfeng in 2020 marked a shift in strategy, with a renewed focus on E-Jiao paste, which has seen significant sales growth due to favorable policy changes [6][19][20]. Recent Developments - The company has launched new products targeting male consumers, such as the "Royal Weichang 1619" brand, and has made strategic acquisitions in the male health supplement sector [9][22]. - Dong-E E-Jiao is also expanding its international presence, having acquired Huaren Pharmaceutical Trading (Hong Kong) Co., Ltd. and established partnerships in Southeast Asia, although overseas revenue remains a small portion of total income [10][24].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 83.65 RMB [7][5]. Core Views - The company has shown resilient growth despite industry pressures, with revenue and net profit for the first three quarters of 2025 reaching 47.7 billion RMB and 12.7 billion RMB, respectively, reflecting year-on-year growth of 4% and 11% [1]. - The company is expected to continue its double-digit growth in the Ejiao series, driven by online channel expansion and consumer recovery [2]. - The company is accelerating its expansion in the tonic product category, with strategic partnerships in various product lines, aiming to transition from a leader in Ejiao to a leader in comprehensive tonics during the 14th Five-Year Plan period [3]. Financial Performance - The sales, management, and R&D expense ratios for the first three quarters of 2025 are 35.2%, 6.1%, and 3.0%, respectively, indicating a continuous optimization in sales expenses and an increase in R&D expenses due to strategic investments [4]. - The operating cash flow for the first three quarters of 2025 is 13.1 billion RMB, slightly higher than net profit, indicating strong cash flow management [4]. Earnings Forecast - The report projects net profits for 2025, 2026, and 2027 to be 18.0 billion RMB, 20.5 billion RMB, and 23.2 billion RMB, respectively, with year-on-year growth rates of 15%, 14%, and 13% [5][11].